It is the consensus opinion of the medical oncology reference committee that these protocols are not considered best practice for this patient population.
AC (DOXOrubicin and CYCLOPHOSPHamide) followed by PACLItaxel (three weekly) with or without trastuzumab
"ECOG 1199r evaluated paclitaxel and docetaxel in the adjuvant setting following 4 cycles of doxorubicin/cyclophosphamide. 4950 patients were randomised to 1 of 4 arms with 3 weekly paclitaxel (3 hour infusion) considered the reference regime – weekly paclitaxel, 3 weekly docetaxel and weekly docetaxel. The results of this trial demonstrated superiority for weekly paclitaxel (DFS/OS) and 3 weekly docetaxel (DFS).
With at least 2 studies in the metastatic setting supporting the superiority of the weekly paclitaxel regime (RR/DFS/OS) it was considered that 3 weekly paclitaxel is an inferior regime in the treatment of breast cancer and should not be used in the adjuvant setting. If a 3 weekly regime is preferable then consideration should be given to a docetaxel containing regime."